News & Features

Tracking treatment trends is important as more women are receiving genetic testing when they are diagnosed with early-stage breast cancer and treatment options are expanding.

Research led by the Wellcome Sanger Institute near Cambridge, UK, has identified 28 new genes that are associated with developmental disorders in children, which could lead to diagnoses for around 500 families.

The researchers’ studies indicated that eight different transcript signatures, regulated by interferon signaling, demonstrated equal accuracy for diagnosing incipient tuberculosis.

FutureNeuro will use Congenica’s clinical genomics analysis software Sapientia to study mutations seen in 40% of childhood epilepsies

Racial disparities in disease, particularly breast cancer, continue to pose a major challenge in healthcare.

Invivoscribe says it aims to accelerate drug development by combining with the company’s in-house expertise in diagnostics development and worldwide access to patients and clinical testing capabilities.

Human Longevity Inc. will sequence and analyze up to 500,000 DNA samples from patients in AstraZeneca clinical trials over 10 years.

The “one-pot” assay uses fluorescence-based detection of RNA from pathogens, can be performed within 30–50 minutes of incubation time, and can reach a limit of detection of 0.1-attomolar RNA concentration.

mRNA-1273 was shown to induce CD4+ T-cells of the Th-1 phenotype 14 days after the second dose was given. Th1-biased CD4+ T-cell response was seen across all age groups, as were rare Th2 phenotype responses.

The ability to generate high-affinity Spike protein binders that block viral interaction with ACE2, but which are highly stable, and small—“to maximize the density of inhibitory domains”—could have multiple advantages over antibodies for direct delivery into the respiratory system.